NZ542408A - Selective cytokine inhibitory drugs for treating disorders of the central nervous system - Google Patents
Selective cytokine inhibitory drugs for treating disorders of the central nervous systemInfo
- Publication number
- NZ542408A NZ542408A NZ542408A NZ54240804A NZ542408A NZ 542408 A NZ542408 A NZ 542408A NZ 542408 A NZ542408 A NZ 542408A NZ 54240804 A NZ54240804 A NZ 54240804A NZ 542408 A NZ542408 A NZ 542408A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- phenyl
- cytokine inhibitory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45237403P | 2003-03-06 | 2003-03-06 | |
PCT/US2004/006782 WO2004080393A2 (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ542408A true NZ542408A (en) | 2009-03-31 |
Family
ID=32990646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ542408A NZ542408A (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1605935A4 (zh) |
JP (1) | JP2006519875A (zh) |
KR (1) | KR100831545B1 (zh) |
CN (1) | CN1780616B (zh) |
AU (1) | AU2004220607B2 (zh) |
BR (1) | BRPI0408113A (zh) |
CA (1) | CA2517845A1 (zh) |
IL (1) | IL170710A0 (zh) |
MX (1) | MXPA05009435A (zh) |
NZ (1) | NZ542408A (zh) |
WO (1) | WO2004080393A2 (zh) |
ZA (1) | ZA200507322B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
MX2020003427A (es) * | 2017-10-18 | 2020-09-14 | Intrabio Ltd | Agentes terapeuticos para enfermedades neurodegenerativas. |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
WO2022098106A1 (ko) * | 2020-11-04 | 2022-05-12 | 주식회사 오에이티씨 | 클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
AR003951A1 (es) * | 1995-05-26 | 1998-09-30 | Pfizer | Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla. |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
JP3568749B2 (ja) * | 1996-12-17 | 2004-09-22 | 株式会社デンソー | 半導体のドライエッチング方法 |
ATE238052T1 (de) * | 1997-07-31 | 2003-05-15 | Celgene Corp | Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
AU2003222034A1 (en) * | 2002-03-20 | 2003-10-08 | Celgene Corporation | (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
KR20050000400A (ko) * | 2002-04-12 | 2005-01-03 | 셀진 코포레이션 | 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도 |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
-
2004
- 2004-03-05 ZA ZA200507322A patent/ZA200507322B/en unknown
- 2004-03-05 KR KR1020057016598A patent/KR100831545B1/ko not_active IP Right Cessation
- 2004-03-05 CA CA002517845A patent/CA2517845A1/en not_active Abandoned
- 2004-03-05 CN CN2004800118192A patent/CN1780616B/zh not_active Expired - Fee Related
- 2004-03-05 NZ NZ542408A patent/NZ542408A/en unknown
- 2004-03-05 MX MXPA05009435A patent/MXPA05009435A/es not_active Application Discontinuation
- 2004-03-05 WO PCT/US2004/006782 patent/WO2004080393A2/en active Application Filing
- 2004-03-05 BR BRPI0408113-7A patent/BRPI0408113A/pt not_active IP Right Cessation
- 2004-03-05 AU AU2004220607A patent/AU2004220607B2/en not_active Ceased
- 2004-03-05 EP EP04717992A patent/EP1605935A4/en not_active Withdrawn
- 2004-03-05 JP JP2006509174A patent/JP2006519875A/ja active Pending
-
2005
- 2005-09-06 IL IL170710A patent/IL170710A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0408113A (pt) | 2006-03-01 |
KR100831545B1 (ko) | 2008-05-21 |
WO2004080393A3 (en) | 2004-12-02 |
EP1605935A4 (en) | 2009-05-20 |
KR20050109971A (ko) | 2005-11-22 |
MXPA05009435A (es) | 2005-11-23 |
ZA200507322B (en) | 2007-03-28 |
AU2004220607A1 (en) | 2004-09-23 |
JP2006519875A (ja) | 2006-08-31 |
IL170710A0 (en) | 2011-08-01 |
CA2517845A1 (en) | 2004-09-23 |
WO2004080393A2 (en) | 2004-09-23 |
EP1605935A2 (en) | 2005-12-21 |
CN1780616A (zh) | 2006-05-31 |
AU2004220607B2 (en) | 2009-06-11 |
CN1780616B (zh) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080227816A1 (en) | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | |
CA2590903A1 (en) | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation | |
US20060106085A1 (en) | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury | |
AU2004220607B2 (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
US20040175382A1 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
US20050182097A1 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases | |
US20070190070A1 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
MXPA06010091A (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
AU2014346877A1 (en) | Compositions and methods for the treatment of viral diseases with PDE4 modulators | |
MXPA06007166A (en) | Immunomodulatory compounds for the treatment of central nervous system disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed |